Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. covers the month of February 2026. The report details the results of the Company's adjourned annual and special meeting of shareholders held on February 12, 2026. The meeting was previously adjourned from January 22, 2026, due to a lack of quorum. As of the record date (December 23, 2025), there were 6,388,604 common shares outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Shareholders representing approximately 29.3% of issued and outstanding common shares (1,868,713 shares) were present, establishing a quorum. All three proposals presented were approved:
- Proposal 1 (Election of Directors): All five nominees (Jody Aufrichtig, Seth Feuerstein, Mark Balkin, Graham Mark Patrick, and Warwick Corden-Lloyd) were elected. Voting support ranged from 89.01% to 89.44% "For" each nominee.
- Proposal 2 (Appointment of Auditors): MNP LLP was appointed as the Company's auditors with 95.39% of votes cast in favor.
- Proposal 3 (Share Consolidation): A special resolution approving the proposed consolidation of the Company's common shares was approved with 75.29% of votes cast in favor.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder meeting.
Investor Verification Checklist
- Verify the specific terms and effective date of the approved share consolidation.
- Confirm the final share count post-consolidation once the transaction is executed.
- Review the press release (Exhibit 99.1) for additional context on the meeting proceedings.
- Monitor future filings for the Company's next financial report, as no financial data was included in this 6-K.